Amerikanische Gesellschaft für Hirudotherapie

Antibacterial non-glycosidase activity of invertebrate destabilase-lysozyme and of its helical amphipathic peptides

Basic science published in Chemotherapy (2006)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Antimikrobielle ResistenzSpeichel-PharmakologieZavalova LL et al. · Chemotherapy, 2006

Abstract

BACKGROUND: Since bactericidal properties of some lysozymes are independent of their glycosidase activity, we have investigated this phenomenon for destabilase-lysozyme (DL) from medicinal leech (Hirudo medicinalis). METHODS: Glycosidase activity was determined on Micrococcus luteus, non-enzymatic antibacterial activity of heat-treated DL and of synthetic peptides alpha1, alpha2 and alpha3 (fragments of its primary structure) on M. luteus, Escherichia coli, Bacillus brevis and Streptomyces chrysomallus. RESULTS: Glycosidase activity disappeared after the heating of native DL at 100 degrees C for 40 min. Antibacterial activity of heat-treated DL for M. luteus MDMSU128 and MDMSU140 expressed as minimal inhibitory concentration was 9.8.10(-8) and 12.10(-8) M, respectively, and to E. coli MDMSU52 11.10(-8) M. Antibacterial activity of synthetic peptide alpha1 for M. luteus MDMSU128 and for E. coli MDMSU52 was 8.3.10(-5) and 4.9.10(-5) M, respectively. CONCLUSION: DL is the first invertebrate lysozyme with combined enzymatic and non-enzymatic antibacterial action.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsAnti-Infective AgentsBacteriaEndopeptidasesGlycoside HydrolasesHirudo medicinalisMicrobial Sensitivity TestsPeptide Fragments

Zusammenfassung

Heat-treated destabilase retains antibacterial activity (MIC 9.8-12x10^-8 M) against M. luteus and E. coli even with glycosidase function abolished.

Warum dies für die Hirudotherapie relevant ist

This study investigated the antibacterial properties of destabilase-lysozyme (DL) from the medicinal leech (Hirudo medicinalis), specifically examining its non-enzymatic, non-glycosidase antibacterial action. It is highly relevant to the leech secretome, demonstrating that heat-treated DL and synthetic peptides derived from its structure retain potent antibacterial activity against pathogens like Micrococcus luteus and Escherichia coli. This reveals that leech-derived molecules possess a dual enzymatic and non-enzymatic defense mechanism. However, the scope is limited to in vitro microbial sensitivity testing of isolated or synthetic leech peptides, providing no data on the efficacy of these compounds in live animal models or clinical hirudotherapy.

Zitation

Antibacterial non-glycosidase activity of invertebrate destabilase-lysozyme and of its helical amphipathic peptides.

Zavalova LL et al. · Chemotherapy, 2006

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.